First dependable anthrax drug gets FDA approval: It is inhaled
Anthrax treatment seems to have got a boost of sort. Right now the whole world seems to be talking about nothing but Emergent BioSolutions’ anthrax treatment.
The news has been broken to a mesmerized world by none other than the Emergent BioSolutions Inc. the company has made it known to all that the U.S. Food and Drug Administration has finally approved its treatment for inhaled anthrax.
The treatment is part of a larger effort by none other than the U.S. Department of Health and Human Services (HHS) to find out with a treatment that could save the life of people affected by anthrax attack.
The company that has reportedly developed, Anthrasil treatment for the anthrax exposure has done it in association with U.S. Department of Health and Human Servicesâ€™ subsidiary known as Biomedical Advanced Research and Development Authority (BARDA). It had won a $160 million contract from Biomedical Advanced Research and Development Authority (BARDA) in the year 2005 to do it.
A Reuters report while talking about it says that the drug is already being stored in the U.S. Strategic National Stockpile, the company said on Wednesday. The report further says that Anthrasil is a sterile solution of purified human immune globulin G (IgG) that targets the anthrax toxins of Bacillus anthracis, the bacteria that causes anthrax disease.